Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma

TAKAHARU KAWAI, MITSUGU KOCHI, MASASHI FUJII, KEIO SONG, KEN HAGIWARA, MEGUMU WATANABE, YORITAKA MATSUNO, HIROSHI SUDA, RENPEI YAGI and TADATOSHI TAKAYAMA
Anticancer Research June 2017, 37 (6) 3301-3306;
TAKAHARU KAWAI
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MITSUGU KOCHI
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kochi.mitsugu{at}nihon-u.ac.jp
MASASHI FUJII
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEIO SONG
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEN HAGIWARA
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MEGUMU WATANABE
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YORITAKA MATSUNO
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI SUDA
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RENPEI YAGI
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TADATOSHI TAKAYAMA
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Kaplan–Meier estimates of overall survival (OS) in all 86 patients. The 5-year OS rate was 83.2% in Stage II and 22.8% in Stage III (p=0.0001).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Kaplan–Meier estimates of disease-free survival (DFS) in all 86 patients. The 5-year DFS rate was 67.9% in Stage II and 29.9% in Stage III (p=0.0007).

Tables

  • Figures
  • Table I.
  • Table II.
  • Table III.
  • Table IV.
  • Table V.
  • Table VI.
  • Table VII.
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 37, Issue 6
June 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma
TAKAHARU KAWAI, MITSUGU KOCHI, MASASHI FUJII, KEIO SONG, KEN HAGIWARA, MEGUMU WATANABE, YORITAKA MATSUNO, HIROSHI SUDA, RENPEI YAGI, TADATOSHI TAKAYAMA
Anticancer Research Jun 2017, 37 (6) 3301-3306;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma
TAKAHARU KAWAI, MITSUGU KOCHI, MASASHI FUJII, KEIO SONG, KEN HAGIWARA, MEGUMU WATANABE, YORITAKA MATSUNO, HIROSHI SUDA, RENPEI YAGI, TADATOSHI TAKAYAMA
Anticancer Research Jun 2017, 37 (6) 3301-3306;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Gamma Knife Radiotherapy of Brain Metastasis Resection Cavities: Outcome Analysis of a Single-center Cohort
  • Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
  • Osteosarcoma of the Diaphysis: A Report from the Cooperative Osteosarcoma Study Group (COSS)
Show more Clinical Studies

Similar Articles

Keywords

  • esophageal cancer
  • Chemoradiotherapy
  • stage II or III patients
  • prognosis
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire